Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of APG-1252 as a Single Agent or in Combination With Other Therapeutic Agent in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma(NHL)

NCT05186012 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT05186012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05186012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of APG-1252 as a Single Agent or in Combination With Other Therapeutic Agent in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma(NHL)
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 14, 2022
Completion date
March 31, 2026
Enrollment
51 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nhl, adult